Replies to post #130778 on Biotech Values

[mcbio]

But I am concerned in the near term that these data will raise expectations unduly for ALNY's PCKS9 phase 1 data readout shortly after the start of 2012. The trial is a single ascending dose in patients not allowed to be taking any cholesterol lowering drugs...

So you think there could be a bit of a sell-off in ALNY after their results and there may be a better buying opportunity after? Market cap is only about $300M now though (enterprise value under $30M according to Yahoo) so I don't think there are a lot of expectations baked into these upcoming results anyways.